Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma
worldwide, representing approximately 30–40% of all cases in different geographic regions …

Although the majority of patients with diffuse large B‐cell lymphoma (DLBCL) can be cured
with the standard immunochemotherapy R‐CHOP, one‐third of them relapses with a dismal …

In patients with diffuse large B-cell lymphoma, MYC rearrangement (MYC-R), MYC
expression, or concurrent expression of MYC and BCL2 is associated with a poorer …

High-grade B-cell lymphomas with MYC, BCL2, and BCL6 rearrangements (triple hit
lymphoma) are uncommon. We studied the clinicopathologic features of 40 patients with …

The designation high-grade B-cell lymphoma traditionally has been used as a general term
for B-cell lymphomas that are morphologically aggressive with many mitotic figures, often a …

The 2016 WHO classification introduced the category of high-grade B-cell lymphoma
(HGBL), which includes one poorly understood subset, blastoid-HGBL. Establishing the …

Mantle cell lymphoma (MCL) with MYC rearrangement (MYC-R) is rare and little is known
about the importance of MYC extra copies (EC) in the absence of MYC-R in MCL patients …

High-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements (double-
/triple-hit lymphoma) have an aggressive clinical course. We investigated the prognostic …

Patients with double-hit or triple-hit lymphoma have a significantly worse prognosis
compared to patients with diffuse large B-cell lymphoma without MYC rearrangement …

Background and aim High-grade B cell lymphomas with concomitant MYC and BCL2 and/or
BCL6 rearrangements (HGBCL-DH/TH) have a poor prognosis when treated with the …